Based on the Real-Life Data of Türkiye; Comparison of Anatomical and Functional Outcomes of Phakic and Pseudophakic Patients in Wet Type Age-Related Macular Degeneration

Overview

Journal Beyoglu Eye J

Publisher Kare Publishing

Specialty Ophthalmology

Date 2023 Jul 31

PMID 37521880

Authors

Havva Erdogan Kaldirim

Abdullah Ozkaya

Levent Karabas

Cengiz Alagoz

Zeynep Alkin

Ozgur Altunay

Sadik Etka Bayramoglu

Selim Bolukbasi

Gokhan Demir

Mehmet Demir

Ali Demircan

Burak Erden

Gurkan Erdogan

Mehmet Erdogan

Erdem Eris

Ismail Umut Onur

Ozen Ayranci Osmanbasoglu

Sezin Ozdogan Erkul

Mine Ozturk

Fatma Savur

Irfan Perente

Kubra Sarici

Nihat Sayin

Dilek Yasa

Ihsan Yilmaz

Zeynep Yilmaz Abdurrahmanoglu

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study was comparison of wet-type age-related macular degeneration in phakic and pseudophakic patients in terms of anatomical and functional success based on the real-life data of Türkiye.

Methods: The multicenter retrospective real-life study data of the. retinal study group were used in this study. Among 867 eyes of 867 patients were included in the study. Patients were divided into two groups according to the status of the lens; phakic group and pseudophakic group. The follow-up period of the two groups, the number of injections at the 1, 2, and 3 years, and changes in the central macular thickness (CMT, μ) and visual acuity (VA, logMAR) of the patients at the beginning, 6, 12, 24, and 36 months were examined.

Results: In our study, the number of injections in the 1, 2, and 3 years, respectively, was 4.2±2.0, 1.8±1.9, and 1.0±1.7 in the phakic group, and 3.9±2.0, 1.7±1.9, and 0.8±1.4 in the pseudophakic group. When the two groups were compared in terms of the number of injections, there was a statistically significant difference in the 1st year, but there was no significant difference in the 2 and 3 years (p=0.001, p=0.350, and p=0.288, respectively). There was no statistically significant difference between the groups in terms of CMT in the baseline, 6, 12, 24, and 36 months (p=0.991, p=0.327, p=0.652, p=0.599, and p=0.873, respectively). Although there was no difference in VA between groups at the beginning (p=0.052), the phakic group showed statistically better VA in controls at 3, 6, 12, 24, and 36 months (p=0.001, p=0.001, p=0.000, p=0.000, and p=0.003, respectively).

Conclusion: Differences in the number of injections and visual results between phakic and pseudophakic patients in wet type AMD may necessitate the creation of different treatment and follow-up protocols.

References

Hikichi T . Time course of development of posterior vitreous detachments after phacoemulsification surgery. Ophthalmology. 2012; 119(10):2102-7. DOI: 10.1016/j.ophtha.2012.03.050. View

Schmidt-Erfurth U, Kaiser P, Korobelnik J, Brown D, Chong V, Nguyen Q . Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2013; 121(1):193-201. DOI: 10.1016/j.ophtha.2013.08.011. View

Neal R, Bettelheim F, Lin C, Winn K, Garland D, Zigler Jr J . Alterations in human vitreous humour following cataract extraction. Exp Eye Res. 2005; 80(3):337-47. DOI: 10.1016/j.exer.2004.09.015. View

Mitchell P, Wang J, Foran S, Smith W . Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002; 109(6):1092-7. DOI: 10.1016/s0161-6420(02)01055-2. View

Laude A, Tan L, Wilson C, Lascaratos G, Elashry M, Aslam T . Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog Retin Eye Res. 2010; 29(6):466-75. DOI: 10.1016/j.preteyeres.2010.04.003. View

Martin D, Maguire M, Ying G, Grunwald J, Fine S, Jaffe G . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897-908. PMC: 3157322. DOI: 10.1056/NEJMoa1102673. View

Hilford D, Hilford M, Mathew A, Polkinghorne P . Posterior vitreous detachment following cataract surgery. Eye (Lond). 2008; 23(6):1388-92. DOI: 10.1038/eye.2008.273. View

Ozkaya A, Alkin Z, Yazici A, Demirok A . Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity. Retina. 2013; 34(5):853-9. DOI: 10.1097/IAE.0000000000000024. View

Boyer D, Antoszyk A, Awh C, Bhisitkul R, Shapiro H, Acharya N . Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(2):246-52. DOI: 10.1016/j.ophtha.2006.10.045. View

10.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

11.

Ferris 3rd F, Fine S, Hyman L . Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102(11):1640-2. DOI: 10.1001/archopht.1984.01040031330019. View

12.

Wang J, Klein R, Smith W, Klein B, Tomany S, Mitchell P . Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology. 2003; 110(10):1960-7. DOI: 10.1016/s0161-6420(03)00816-9. View

13.

Baek J, Cho H, Cho S, Kim C, Kim J . Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Retina. 2013; 33(3):467-73. DOI: 10.1097/IAE.0b013e3182753b2a. View

14.

Ozkaya A, Alkin Z, Yilmaz I, Yazici A . Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results. Saudi J Ophthalmol. 2015; 29(3):182-6. PMC: 4487941. DOI: 10.1016/j.sjopt.2014.12.002. View

15.

Goldenberg D, Giblin F, Cheng M, Chintala S, Trese M, Drenser K . Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina. 2010; 31(2):393-400. PMC: 3057916. DOI: 10.1097/IAE.0b013e3181e586b2. View

16.

Brown D, Michels M, Kaiser P, Heier J, Sy J, Ianchulev T . Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116(1):57-65.e5. DOI: 10.1016/j.ophtha.2008.10.018. View

17.

Zhang X, Lai T . Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration. Biomed Res Int. 2018; 2018:9640131. PMC: 5846359. DOI: 10.1155/2018/9640131. View

18.

Algvere P, Marshall J, Seregard S . Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand. 2006; 84(1):4-15. DOI: 10.1111/j.1600-0420.2005.00627.x. View

19.

Wang J, Fong C, Rochtchina E, Cugati S, de Loryn T, Kaushik S . Risk of age-related macular degeneration 3 years after cataract surgery: paired eye comparisons. Ophthalmology. 2012; 119(11):2298-303. DOI: 10.1016/j.ophtha.2012.07.003. View

20.

Neudorfer M, Eshel Fuhrer A, Zur D, Barak A . The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. Indian J Ophthalmol. 2018; 66(12):1802-1807. PMC: 6256908. DOI: 10.4103/ijo.IJO_373_18. View